Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis

Table of Contents

• RA vs. OA: Two Different Diseases
• Rheumatoid Arthritis: Pathophysiology
• Osteoarthritis: Pathophysiology
• Diagnosis and Classification
• Conventional Treatment for RA
• Conventional Treatment for OA
• Platelet-Rich Plasma (PRP)
• Stem Cell Therapy
• Peptides and Small Molecules
• Other Regenerative Approaches
• Evidence Summary Table
• What to Expect from Treatment
• Frequently Asked Questions

RA vs. OA: Two Different Diseases

Arthritis is not a single disease. It is a category covering over 100 joint conditions, but rheumatoid arthritis and osteoarthritis account for the vast majority of cases and carry the greatest burden of disability. Despite sharing the word “arthritis,” their causes, mechanisms, and optimal treatments are fundamentally different.

Confusing the two leads to mismanagement. A patient treated for OA who actually has RA may experience ongoing joint destruction while waiting for symptom relief. A patient given immunosuppressive DMARD therapy for mechanical wear risks unnecessary side effects. Accurate diagnosis is the foundation of effective care.

Rheumatoid Arthritis: Pathophysiology

RA begins with a loss of immune tolerance to self-antigens, particularly citrullinated proteins. In genetically susceptible individuals (especially those carrying HLA-DRB1 “shared epitope” alleles), environmental triggers, most notably cigarette smoking, appear to initiate protein citrullination in the lungs or other mucosal surfaces. This generates anti-citrullinated protein antibodies (ACPA), detectable in serum years before clinical joint symptoms appear.

Once synovial inflammation is established, a self-amplifying cascade drives joint destruction. Activated CD4+ T cells stimulate B cells to produce autoantibodies (RF, ACPA) and drive macrophage activation. Macrophages release pro-inflammatory cytokines, primarily TNF-alpha, IL-1, and IL-6. These cytokines stimulate synovial fibroblasts to proliferate, forming the invasive pannus tissue that erodes cartilage and bone. Osteoclast activation, driven by receptor activator of NF-kB ligand (RANKL), accelerates periarticular bone loss.

The synovium transforms from a thin membrane into an aggressive, tumor-like tissue. Synovial fibroblasts in RA acquire an invasive phenotype independent of lymphocyte signaling, which partly explains why remission is difficult to sustain and why certain patients do not respond fully to biologic therapies targeting T or B cells.

Genetic and Environmental Risk

Heritability of RA is estimated at 40-60%, with HLA-DRB1 alleles accounting for roughly 30% of genetic risk. Non-HLA loci, including PTPN22, CTLA4, and STAT4, contribute additional susceptibility. A 2019 genome-wide association study published in Nature Genetics identified over 100 RA risk loci, pointing to multiple immune regulatory pathways involved in disease onset.

Cigarette smoking is the strongest modifiable environmental risk factor, roughly doubling RA risk in genetically susceptible individuals. Periodontal disease (via Porphyromonas gingivalis citrullination activity), gut dysbiosis, and hormonal factors also appear to contribute. Women are affected two to three times more often than men, suggesting a role for sex hormones in immune regulation.

Osteoarthritis: Pathophysiology

OA was historically described as simple “wear and tear,” but this framing is now considered inadequate. OA involves active biological remodeling of the entire joint unit, including articular cartilage, subchondral bone, synovium, ligaments, and periarticular muscles. It is better understood as a failure of joint homeostasis driven by a combination of mechanical overload and metabolic dysfunction.

At the cellular level, chondrocytes shift from a quiescent maintenance state toward a hypertrophic, catabolic phenotype. They upregulate matrix metalloproteinases (MMPs) and ADAMTS enzymes that degrade aggrecan and type II collagen, the primary structural components of cartilage. This degradation outpaces repair capacity, leading to progressive cartilage thinning. Subchondral bone undergoes concurrent remodeling, with increased vascularity and altered stiffness that further disrupts load distribution across the joint surface.

Low-grade synovial inflammation, while less dramatic than in RA, is present in most OA joints and contributes meaningfully to pain. Synovial macrophages release IL-1beta and TNF-alpha in OA joints, creating a local inflammatory microenvironment. A 2021 review in Nature Reviews Rheumatology highlighted that OA synovitis correlates with pain severity and structural progression, challenging the view that OA is a purely mechanical condition.

Risk Factors for OA

Age is the strongest risk factor. Cartilage repair capacity decreases with age due to reduced chondrocyte numbers and mitochondrial dysfunction. Obesity amplifies risk through both mechanical loading and systemic metabolic effects: adipokines from visceral fat directly promote chondrocyte catabolism. A body mass index above 30 roughly quadruples knee OA risk compared to normal weight.

Prior joint injury is a significant independent risk factor. Post-traumatic OA develops in 50-80% of individuals following ligament or meniscal injuries, according to data published in Osteoarthritis and Cartilage (2019). Female sex, occupational joint loading, and certain genetic polymorphisms in collagen and cartilage matrix genes also increase susceptibility.

Diagnosis and Classification

Diagnosing RA

The 2010 ACR/EULAR classification criteria for RA replaced the older 1987 criteria to allow earlier diagnosis before erosive disease develops. The scoring system considers the number and type of joints involved, serologic findings (RF, ACPA), acute phase reactants (CRP, ESR), and symptom duration. A score of 6 or more out of 10 classifies a patient as having definite RA.

Anti-CCP (cyclic citrullinated peptide) antibodies have approximately 95% specificity for RA and can precede clinical onset by years. Their presence alongside joint symptoms strongly supports early treatment initiation. Seronegative RA (negative RF and anti-CCP) exists in roughly 20-30% of cases and can be diagnostically challenging.

Diagnosing OA

OA diagnosis is primarily clinical and radiographic. The ACR criteria for knee OA require knee pain plus at least three of the following: age over 50, morning stiffness under 30 minutes, crepitus on motion, bony tenderness, bony enlargement, or absence of warmth. Radiographic OA is classified by the Kellgren-Lawrence (KL) grading system, from grade 0 (normal) to grade 4 (severe joint space loss with large osteophytes).

MRI is increasingly used to detect early cartilage changes before radiographic findings appear, and is particularly relevant for clinical trials and surgical decision-making. Synovial fluid analysis in OA typically shows a non-inflammatory profile (white cell count under 2,000 cells/mm3), which helps differentiate it from inflammatory arthropathies.

Conventional Treatment for RA

The treatment goal in RA is remission or low disease activity, guided by a treat-to-target (T2T) strategy formalized in ACR and EULAR guidelines. Disease activity is measured regularly using validated scores such as the DAS28 (Disease Activity Score), and therapy is escalated until the target is reached.

Conventional DMARDs

Methotrexate (MTX) remains the anchor drug for RA. It is typically the first DMARD initiated after diagnosis, at doses of 7.5-25 mg per week. MTX works through multiple mechanisms including folate pathway inhibition and adenosine pathway modulation, resulting in reduced inflammation and slowed joint destruction. A 2019 Cochrane review of 17 trials confirmed that MTX significantly reduces disease activity and structural progression versus placebo.

Other conventional DMARDs include leflunomide, sulfasalazine, and hydroxychloroquine, often used in combination. Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) can be as effective as biologic therapy in some patients and is substantially less expensive, according to a landmark 2013 trial published in The New England Journal of Medicine.

Biologic DMARDs

Biologic agents target specific cytokines or immune cells in the RA cascade. TNF inhibitors (etanercept, adalimumab, infliximab, certolizumab, golimumab) were the first approved and remain widely used. IL-6 receptor inhibitors (tocilizumab, sarilumab) are effective, particularly in patients who fail TNF inhibition. Abatacept (CTLA4-Ig) targets T cell co-stimulation, and rituximab depletes B cells.

Biologic therapy combined with MTX produces ACR50 responses (50% improvement in disease activity measures) in 40-60% of patients, with ACR70 responses in 25-40%, based on pooled data from pivotal trials. These are meaningful improvements, but a substantial proportion of patients do not achieve sustained remission.

JAK Inhibitors

Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, and upadacitinib, block intracellular signaling downstream of multiple cytokine receptors. They are oral agents that offer an alternative to injectable biologics. A 2017 Phase 3 trial of upadacitinib published in The Lancet (SELECT-BEYOND, n=499) showed ACR20 rates of 65% and remission rates of 25% in patients who had failed biologic therapy.

The FDA and EMA have added safety warnings regarding cardiovascular events, venous thromboembolism, and malignancy risk with JAK inhibitors, based on the ORAL Surveillance trial (2021, NEJM), which showed higher rates of major adverse cardiovascular events and cancers with tofacitinib versus TNF inhibitors in a high-cardiovascular-risk population. These drugs are generally reserved for patients who have failed or cannot tolerate conventional DMARDs and at least one biologic.

Conventional Treatment for OA

OA treatment guidelines from ACR (2019 update) and OARSI (2019) strongly recommend exercise therapy, weight management, and physical therapy as first-line interventions. These have the best risk-benefit ratios and should be initiated before or alongside any pharmacologic therapy. A 2017 meta-analysis in JAMA Internal Medicine found that land-based exercise reduces knee OA pain by an average of 12 points on a 100-point scale (NRS).

Pharmacologic Options

Topical NSAIDs (diclofenac gel) are the preferred first pharmacologic step for knee and hand OA, offering similar efficacy to oral NSAIDs with much lower systemic exposure. Oral NSAIDs are conditionally recommended but carry significant gastrointestinal, cardiovascular, and renal risks with long-term use. Duloxetine is recommended for patients with widespread pain or a significant central sensitization component.

Intra-articular corticosteroid injections provide short-term pain relief (typically 4-6 weeks) but have not been shown to slow structural progression. A 2017 JAMA study (n=140) found that repeated corticosteroid injections over 2 years actually resulted in greater cartilage volume loss compared to saline injections, raising concerns about long-term use. Intra-articular hyaluronic acid (viscosupplementation) has inconsistent evidence; ACR 2019 guidelines conditionally recommend against it for knee OA due to small effect sizes.

Surgical Options

Total joint replacement (TJR) is effective for end-stage OA with severe pain and functional limitation unresponsive to conservative management. Knee and hip replacements have over 90% implant survival at 10 years. Arthroscopic surgery (debridement, lavage) is not recommended for knee OA per ACR and NICE guidelines, based on multiple sham-controlled trials showing no benefit over conservative care.

Platelet-Rich Plasma (PRP)

PRP is prepared by centrifuging a patient’s own blood to concentrate platelets, which contain growth factors including PDGF, TGF-beta, IGF-1, VEGF, and FGF. When injected into a joint, these growth factors may modulate the local inflammatory environment, stimulate chondrocyte activity, and inhibit catabolic enzymes.

Evidence in Osteoarthritis

The evidence base for intra-articular PRP in knee OA has grown substantially over the past decade. A 2021 network meta-analysis published in The BMJ (n=9,228 across 152 trials) found that PRP produced the largest pain reduction at 12 months among all intra-articular interventions, outperforming hyaluronic acid and corticosteroids. The mean difference over placebo on the WOMAC pain scale was clinically significant.

A 2022 double-blind RCT in JAMA (n=288) comparing PRP, hyaluronic acid, and saline in knee OA found that PRP did not significantly outperform saline at 12 months on the KOOS pain subscale. This trial tempered enthusiasm somewhat and underscored the importance of patient selection, PRP preparation method, and injection technique as variables affecting outcome.

Key variables affecting outcomes include leukocyte content (leukocyte-poor PRP appears better tolerated in joints), platelet concentration, number of injections, and baseline disease severity. Patients with early to moderate OA (KL grade 1-3) appear to derive more benefit than those with severe structural disease (KL grade 4).

Evidence in Rheumatoid Arthritis

Research on PRP in RA is limited and the theoretical rationale is less clear. RA involves an active autoimmune process, and introducing concentrated growth factors and cytokines into an already inflamed joint could theoretically amplify inflammation. Small pilot studies have suggested possible benefit in finger joints, but no adequately powered RCTs exist. PRP for RA joints should be considered investigational at this stage.

Stem Cell Therapy

Mesenchymal stem cells (MSCs) are multipotent stromal cells found in bone marrow, adipose tissue, umbilical cord tissue (Wharton’s jelly), and synovial membrane. They have two properties of relevance to arthritis treatment: the ability to differentiate toward chondrogenic lineages, and potent immunomodulatory activity through paracrine signaling (secretion of anti-inflammatory cytokines and extracellular vesicles).

MSC Therapy in OA

A 2020 systematic review in Stem Cells Translational Medicine analyzed 23 clinical studies of MSC injection for knee OA and found consistent signals of pain reduction and functional improvement at 6-12 months. MRI-based studies in several trials suggested partial cartilage regeneration, though image interpretation requires caution given variability in scoring methods.

A 2019 Phase 2 RCT by Pers et al., published in EBioMedicine (n=18), demonstrated that adipose-derived MSC injection in knee OA produced significant improvements in WOMAC and VAS pain scores at 12 months, with MRI showing cartilage signal changes in treated knees. However, sample sizes in most trials remain small.

The source of MSCs (autologous vs. allogeneic), cell dose, preparation method, and delivery technique (injection vs. scaffold-based implantation) all influence outcomes significantly. Umbilical cord-derived MSCs (UC-MSCs) are increasingly used due to higher proliferative capacity and lower immunogenicity, and can be banked and deployed off-the-shelf, unlike autologous preparations that require individual processing.

MSC Therapy in RA

The immunomodulatory properties of MSCs make them particularly relevant for RA. MSCs suppress T cell proliferation, shift the balance from Th17 toward Treg cells, and inhibit B cell differentiation, actions that could interrupt the RA autoimmune cascade. A 2023 Phase 1/2 trial published in Annals of the Rheumatic Diseases (n=36) evaluated intravenous UC-MSC infusions in patients with active RA refractory to at least two DMARDs. ACR20 response at 24 weeks was achieved in 52.8% of patients, with an acceptable safety profile.

Intravenous MSC delivery for RA differs mechanistically from intra-articular injection for OA. Systemic delivery targets the immune system broadly rather than providing local joint support. Most MSCs do not engraft long-term after IV infusion; their benefit appears to be mediated primarily through transient paracrine effects on immune cells in lymphoid organs and inflamed tissues.

Hematopoietic Stem Cell Transplantation (HSCT) for RA

Autologous HSCT, which involves immune ablation followed by reconstitution with the patient’s own hematopoietic stem cells, has been studied in severe, refractory RA since the late 1990s. The goal is to “reset” the autoreactive immune system. A 2013 long-term follow-up study from the EULAR registry reported drug-free remission in 10-20% of treated patients at 5 years. HSCT carries significant treatment-related morbidity and is reserved for patients with very aggressive, refractory disease who have failed multiple biologics.

Peptides and Small Molecules

BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protein. In animal studies, it has shown consistent anti-inflammatory effects, upregulation of growth hormone receptor expression, and acceleration of tendon and ligament healing. A 2018 rodent study in Journal of Physiology and Pharmacology demonstrated reduced joint inflammation and improved mobility in collagen-induced arthritis models.

Human clinical trial data for BPC-157 is essentially absent for arthritis. The peptide is not approved by any major regulatory agency and is currently available only through compounding pharmacies or research suppliers. Its use in clinical practice is off-label and experimental. Claims about BPC-157 in humans should be treated with caution until controlled trials are completed.

TB-500 (Thymosin Beta-4)

Thymosin beta-4 is an endogenous peptide involved in actin polymerization, cell migration, and tissue repair. It has shown anti-inflammatory and angiogenic properties in preclinical studies. Synthetic versions (TB-500) are used experimentally for soft tissue injuries. Relevant to OA, a 2020 study in Osteoarthritis and Cartilage found that thymosin beta-4 reduced synovial inflammation and cartilage degradation in a mouse OA model by inhibiting NF-kB signaling. Human evidence is lacking.

Low-Dose Naltrexone (LDN)

LDN (typically 1.5-4.5 mg/day, compared to the 50 mg anti-addiction dose) acts as a transient opioid receptor antagonist, triggering a rebound upregulation of endogenous opioid tone and modulation of microglial/macrophage activity via Toll-like receptor 4 (TLR4) antagonism. This makes it relevant for both inflammatory and pain conditions.

A 2020 pilot RCT published in Pain Medicine (n=40) evaluated LDN for fibromyalgia and chronic widespread pain and found significant pain reduction. RA-specific LDN trials are limited to case reports and small open-label series. A 2018 review in Pharmacological Research summarized preclinical data showing LDN reduces TNF-alpha, IL-6, and NF-kB activity in inflammatory models, suggesting biological plausibility for RA application.

Other Regenerative Approaches

Prolotherapy

Prolotherapy involves injection of an irritant solution (typically dextrose) into ligamentous and tendinous attachments around a joint to stimulate a local healing response. A 2016 RCT in Journal of Alternative and Complementary Medicine (n=90) found that dextrose prolotherapy improved knee OA pain and function scores significantly more than blinded saline injection at 52 weeks. Evidence is Moderate for OA but limited for RA.

Hyperbaric Oxygen Therapy (HBOT)

HBOT involves breathing 100% oxygen in a pressurized chamber (typically 1.5-2.4 atmospheres). Proposed mechanisms in arthritis include reduced hypoxia in inflamed synovium, inhibition of NF-kB activation, and enhanced neutrophil killing of pathogens. A 2022 systematic review in Frontiers in Medicine found seven small studies of HBOT in RA, with mixed results and significant methodological limitations. Evidence remains Preliminary.

Dietary and Nutritional Interventions

Anti-inflammatory dietary patterns have documented effects on RA and OA outcomes. A Mediterranean diet intervention in a 2018 RCT published in Annals of the Rheumatic Diseases (n=66) produced meaningful reductions in DAS28 scores and self-reported pain in RA patients over 12 weeks compared to a standard Western diet. Omega-3 supplementation (2-4 g EPA+DHA daily) has been shown in multiple small RCTs to reduce NSAID use in RA, with a 2012 meta-analysis in Annals of the Rheumatic Diseases confirming morning stiffness and joint tenderness reductions.

For OA, a 2021 Cochrane review on dietary supplements found low to moderate evidence for glucosamine sulfate and chondroitin sulfate in reducing pain, but significant heterogeneity between trials and industry funding concerns complicate the picture. Curcumin at 1,500 mg/day showed comparable pain reduction to ibuprofen 1,200 mg/day in a 2014 Thai RCT (n=367), with a better gastrointestinal side effect profile.

Evidence Summary Table

What to Expect from Treatment

Setting Realistic Goals for RA

Modern RA treatment, using a treat-to-target approach with early aggressive DMARD therapy, has dramatically changed outcomes over the past two decades. Achieving remission is a realistic goal for many patients, particularly those diagnosed early (within 3-6 months of symptom onset) and started on effective therapy promptly. The window of opportunity concept suggests that early intervention, before the establishment of persistent synovitis and fibroblast-driven pannus, produces better long-term structural outcomes.

For patients who reach remission and sustain it for 6-12 months, gradual dose reduction or tapering of biologic therapy is possible and can succeed in 30-40% of cases, according to a 2016 Cochrane review. Full drug discontinuation remains achievable in a minority, underlining the importance of ongoing monitoring even in apparent remission.

Setting Realistic Goals for OA

OA cannot currently be reversed with any available therapy, conventional or regenerative. The realistic treatment goals are pain reduction, functional improvement, slowing of structural progression, and delaying or avoiding joint replacement surgery. Patients with early-stage OA (KL 1-2) and relatively preserved cartilage are the best candidates for regenerative interventions like PRP or MSC therapy.

Patients with KL grade 3-4 disease and severe symptoms have lower response rates to regenerative therapies and should have joint replacement discussed as part of their care plan. Regenerative interventions in advanced OA may still provide temporary symptom relief but are unlikely to produce structural restoration at this stage of disease.

Treatment Sequence and Integration

For most patients, regenerative therapies should be considered adjuncts to, not replacements for, evidence-based conventional care. In OA, this means ensuring an adequate exercise and weight management program is in place before or alongside any injection therapy. In RA, MSC trials are generally conducted in patients who have failed conventional treatment, which remains the appropriate paradigm for most clinical settings outside of specialized research centers.

Patients considering regenerative treatments should be evaluated by a specialist with experience in both conventional rheumatologic care and regenerative medicine to ensure appropriate patient selection and to monitor for adverse effects. Unregulated clinic offerings of stem cell or PRP treatments without diagnostic workup or outcome tracking are a significant quality concern.

Frequently Asked Questions

Can PRP cure osteoarthritis?

No. PRP can reduce pain and improve function for months to over a year in some patients with knee OA, but it does not reverse cartilage loss or halt structural progression in a clinically proven way. It is best understood as a symptom-modifying treatment with potential disease-modifying properties that require larger, longer trials to confirm.

Is stem cell therapy for arthritis safe?

Intra-articular MSC injections and IV MSC infusions have generally been well tolerated in published clinical trials, with low rates of serious adverse events. The most common side effects are temporary post-injection flares of joint pain. Long-term safety beyond 2-3 years is less well characterized. Patients should seek treatment through registered clinical trials or established academic medical centers where outcomes are tracked systematically.

Do I need to stop my DMARD before trying a regenerative therapy?

This depends on the specific therapy. For intra-articular PRP in OA, DMARDs are generally not an issue since the indication is different from RA. For MSC therapy in RA, most clinical trials have allowed continuation of conventional DMARDs at stable doses, with MSC treatment added on top. Stopping DMARDs independently is strongly discouraged in RA, as disease flares can cause irreversible joint damage.

How many PRP injections are needed for knee OA?

Most clinical protocols use 1-3 injections given 1-4 weeks apart, with a possible repeat series at 6-12 months if response is positive. No standardized protocol has been validated across trials. The optimal number of injections, interval, and total dose remain areas of active investigation.

Can diet alone control RA?

Diet is a meaningful adjunct but cannot substitute for DMARD therapy in established RA. Anti-inflammatory dietary patterns (Mediterranean diet, elimination of ultra-processed foods) can reduce inflammatory markers and symptom burden in small trials, but no diet has been shown to prevent joint erosions in the absence of pharmacologic treatment. Dietary optimization should be pursued alongside, not instead of, evidence-based medical therapy.

What distinguishes a legitimate regenerative clinic from a problematic one?

Legitimate programs enroll patients in structured protocols with defined outcome measures, informed consent covering experimental status and risks, follow-up visits to track results, and referral back to rheumatologic care if the condition worsens. Red flags include guaranteed cure claims, no diagnostic workup before treatment, lack of follow-up protocols, no disclosure of experimental status, and prices far exceeding standard of care without justification.

Related Reading

• BPC-157 Benefits: What the Research Actually Shows
• Fibromyalgia: Causes, Diagnosis, and the Complete Treatment Guide
• Hyperbaric Oxygen Therapy (HBOT): How It Works, What It Treats, and What the Evidence Shows
• Joint Pain: Causes, Diagnosis, and the Full Treatment Spectrum
• Low Dose Naltrexone (LDN): A Comprehensive Guide to Uses, Dosing, Evidence, and Side Effects
• Osteoarthritis: What It Is, Why It Progresses, and How Regenerative Medicine Is Changing Treatment